top of page
    • Apr 16

Ultragenyx's Emil Kakkis on this week's Angelman syndrome data, rare disease treatment modalities, and more

Emil Kakkis summarizes Ultragenyx's Angelman syndrome update at AAN, discusses use cases for various treatment modalities, and gives his take on the current state of rare disease drug development.



Comments

Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

@BiotechTVHQ

BiotechTV

BiotechTVHQ

@BiotechTV

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

NYSE_logo_large_no reg_378x197 (1).png

The NYSE is the world’s largest stock exchange, offering icons and entrepreneurs the opportunity to raise capital and change the world. Our listed companies form a powerful community committed to good governance and societal impact. Industry-leading trading technology, combined with the guidance of experienced traders creates higher market quality for NYSE-market participants

Visit NYSE

bottom of page